NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$5.25
+0.04 (+0.77 %)
(As of 06/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.10
$5.40
50-Day Range
$1.93
$2.63
52-Week Range
$1.15
$6.57
Volume358,611 shs
Average Volume1.02 million shs
Market Capitalization$471.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
30 days | 90 days | 365 days | Advanced Chart
Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.


OncoCyte logo

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

586th out of 2,100 stocks

Diagnostic Substances Industry

9th out of 35 stocks

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Is OncoCyte a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte
or view top-rated stocks.

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) posted its quarterly earnings data on Sunday, May, 16th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.05. OncoCyte had a negative net margin of 1,123.40% and a negative trailing twelve-month return on equity of 46.76%.
View OncoCyte's earnings history
.

How has OncoCyte's stock price been impacted by Coronavirus (COVID-19)?

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OCX shares have increased by 145.3% and is now trading at $5.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OCX?

7 analysts have issued 12-month price objectives for OncoCyte's shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate OncoCyte's share price to reach $6.17 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price.
View analysts' price targets for OncoCyte
or view top-rated stocks among Wall Street analysts.

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 61, Pay $978.35k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Ms. Padma Sundar, Chief Commercial Officer
  • Ms. Li Yu, VP, Controller & Principal Accounting Officer
  • Mr. William Annett, Advisor (Age 67)
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Science Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 68)
  • Ms. Sara Riordan, Director of Medical Education

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of retail and institutional investors. Top institutional investors include Pura Vida Investments LLC (13.75%), BlackRock Inc. (5.59%), Orbimed Advisors LLC (2.36%), Schonfeld Strategic Advisors LLC (1.83%), Geode Capital Management LLC (1.28%) and Nuveen Asset Management LLC (1.10%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte
.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including Penbrook Management LLC, GSA Capital Partners LLP, Morgan Stanley, BNP Paribas Arbitrage SA, and The Manufacturers Life Insurance Company.
View insider buying and selling activity for OncoCyte
or view top insider-selling stocks.

Which major investors are buying OncoCyte stock?

OCX stock was acquired by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Orbimed Advisors LLC, Schonfeld Strategic Advisors LLC, BlackRock Inc., GW&K Investment Management LLC, AWM Investment Company Inc., Nuveen Asset Management LLC, and Parian Global Management LP. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte
or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $5.25.

How much money does OncoCyte make?

OncoCyte has a market capitalization of $471.59 million and generates $1.22 million in revenue each year. The biotechnology company earns $-29,930,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does OncoCyte have?

OncoCyte employs 51 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

Where are OncoCyte's headquarters?

OncoCyte is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515 or via email at [email protected]


This page was last updated on 6/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.